



Berlin/Germany August 24–26, 2023

## Targeted Therapy with IR:

How does IR continue to differentiate and add value, distinct from other minimally invasive targeted therapies?

Stephen Solomon, MD Chief of Interv Radiol Memorial Sloan Kettering New York, New York


#### Conflicts of Interest

- Consultant: GE Healthcare, Johnson & Johnson, XACT Robotics, Aperture Medical, Orchestra Biomed, MedX Incubator, Microbot, Merck
- Grants: GE Healthcare, Angio Dynamics, Elesta
- Shareholder: Johnson & Johnson, Lantheus, Aspire Bariatrics, Aperture Medical



## **Therapeutic Options**







Imaging discovering tumors when tumors are smaller





# Lung Cancer Screening has Led to Smaller Cancers





Treatment for oligometastatic/oligoprogressive or multifocal disease is growing






## Organ Preservation

#### Shift from Anatomic to Non-Anatomic Resection

 Diagnostic imaging discovers lesions smaller


- Organ preservation is essential
- Data showing equivalence of non-anatomic resection





### Lobectomy vs Wedge

- Anatomic (lobectomy) vs Nonanatomic (wedge) resection
- Smaller surgery is an opportunity to preserve lung function.





# Lung Palpation to Locate the Cancer for Non-Anatomic (ie Wedge) Resection



## Image-guided Ablation








64 year old woman with solitary metastasis from colon cancer (2014)


63 year old woman with solitary metastasis from colon cancer (Dec 2020)





#### **Ablation Patient**



#### **Ablation Patient**











#### **Surgery Patient**





#### Molecular Image-Guided Interventions


#### Intra-Procedural PET for Real-Time Determination of Success



## With Imaging, IR Scales Small Very Well


#### **Radiation Changes**





Oct, 2017

## Inside-out $\leftarrow \rightarrow$ Outside-in





## Organ Preservation

Pulmonary Function Tests

Glomerular Filtration Rate

Liver Function Tests





Intratumoral Therapies


Anti-viral Immunotherapy Nanotherapy







## Intratumoral Delivery

a







Advantages

Practical


Practical


 High therapeutic index

Low toxicity



#### IS3R 2023 | Berlin/Germany | August 24–26, 2023 Tumor/Background: 1000x improved with IA over IV Radioisotope Delivery





## Favorable Trends for IR

- Imaging discovering tumors when tumors are smaller
- Treatment for oligometastatic/oligoprogressive or multifocal disease is growing
- Organ Preservation
- Intratumoral Therapies (eg Nanotherapies, Immunostimulants, Anti-virals) are developing but facing delivery challenges and systemic toxicities.



